TRVI

Trevi TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$1.22

-91.0% vs current

Most likely

Base case

60%

Probability

Target price

$0.61

-95.5% vs current

B-

Bear case

20%

Probability

Target price

$0.30

-97.8% vs current

AI sentiment snapshot

Latest data as of 2025-11-29

AI commentary

Market tone is cautious-to-negative: investors focus on near-term financing and trial readouts while low liquidity amplifies moves. Press and filings emphasize funding needs and program timelines.

RankAlpha Sentiment AI - 2025-11-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-03-31catalystCash runway / financing eventHigh impact

Need for additional financing or successful raise alters dilution expectations and valuation [#10Qp12].

2026-06-30eventAdvancement or readout from CNS pipelineHigh impact

Potential clinical data update or program decision for lead CNS asset could materially move the stock; Trevi focuses on CNS candidates [#10Qp12].

2026-12-31catalystRegulatory setback or negative preclinical signalHigh impact

Adverse safety/efficacy data from trials or regulatory feedback could trigger sharp downside [#PR-2025-09-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-29 • Updated nightlySource: Internal modelMethodology